Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Pfizer
- Study ID
- NCT01976364
- Phase
- PHASE3
- Status
- Completed
Conditions
- Arthritis, Psoriatic
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Tofacitinib — DRUGTofacitinib 5 mg tablet twice daily
- Tofacitinib — DRUGTofactinib 10 mg tablet twice daily
- Methotrexate — DRUGMethotrexate 7.5-20 mg weekly
- Placebo Methotrexate — DRUGPlacebo to match active methotrexate orally once a week
Study Details
This is a Phase 3, long-term open-label extension study to evaluate the safety, tolerability and efficacy of tofacitinib in subjects with active PsA who have previously participated in randomized studies of tofacitinib for this indication. This study will include a sub-study to evaluate the efficacy, safety and tolerability of tofacitinib 5 mg BID administered as monotherapy after methotrexate withdrawal compared to tofacitinib 5 mg BID continued in combination with methotrexate. The sub-study will be available to subjects who have completed at least 24 months of participation in the open-label extension study and meet eligibility criteria for the sub-study.
Key Dates
- Start date
- Feb 17, 2014
- Status verified
- May 2020
- Primary completion
- May 20, 2019
- Completion
- May 20, 2019
Study Design
- Enrollment
- 686 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Tofacitinib
Primary Outcome Measure
Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Date of first dose of study medication up to 48 months (36 months of main study and 12 months of sub-study) ]
Locations (43)
Find similar trials in Birmingham, AL
Related Studies
- IMPACT - AndHealth Autoimmune Research RegistryRecruiting · AndHealth · Columbus, Ohio
- Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponsePHASE3 · Recruiting · MoonLake Immunotherapeutics AG · Avondale, Arizona
- A Long-term Extension (LTE) Study of Guselkumab in Pediatric ParticipantsPHASE3 · Recruiting · Janssen Research & Development, LLC · Atlanta, Georgia
- A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic ArthritisPHASE3 · Recruiting · Janssen Research & Development, LLC · Glendale, Arizona